1. Introduction {#sec1-cancers-11-01457}
===============

Urothelial carcinoma (UC) is the sixth most common cancer in the world, with a particularly high incidence in southwestern Taiwan. The majority of UCs are found in the urinary bladder, while tumors from the upper urinary tract (ureter or renal pelvis, known as UTUC) account for 5--10% of all UCs worldwide \[[@B1-cancers-11-01457]\], but 20% in Taiwan \[[@B2-cancers-11-01457]\]. The two principle forms of UC are generally differentiated according to the depth of muscle invasion: non-muscle invasive and muscle invasive cancer. One of the major challenges in treating UC is dealing with the high recurrence rate of superficial cancers, and more than 40% of all UC patients will recur within 5 years, even after surgical treatment \[[@B3-cancers-11-01457]\]. This may be attributed to the presence of drug-resistant cancer stem cells (CSCs), which are characterized by the presence of CD44 \[[@B4-cancers-11-01457],[@B5-cancers-11-01457]\].

CD44 is an integral cell membrane glycoprotein identified as a key biomarker for the isolation and characterization of CSCs \[[@B4-cancers-11-01457],[@B6-cancers-11-01457],[@B7-cancers-11-01457]\]. CD44, a receptor for the extracellular matrix polysaccharide hyaluronate, is involved in several physiological processes---including intercellular adhesion, cell-matrix adhesion, and cell migration---as well as tumor cell invasion and metastasis \[[@B8-cancers-11-01457]\]. Therefore, elucidating the molecular mechanism(s) underlying the formation of CSCs in UC could lead to the development of novel therapeutic methods to deal with this deadly disease.

Epigenetic modification is considered a hallmark of cancer, due to its roles in cellular carcinogenesis and tumor progression \[[@B9-cancers-11-01457]\]. One such modification involves the regulation of microRNAs (miRNAs or miRs), resulting in the generation of small (20--23 nucleotides), non-coding, single-stranded RNAs, which induce the degradation or translational inhibition of homologous target mRNAs by binding their 3′-untranslated region (UTR) \[[@B10-cancers-11-01457]\]. Researchers have also recently identified another mechanism of miRNA regulation, namely, competing endogenous RNAs (ceRNAs), in which an mRNA sharing a common miRNA response element (MRE) with another mRNA, regulate one another by competing for the same miRNA \[[@B11-cancers-11-01457]\]. In this ceRNA mechanism, the 3′UTR of the mRNA could act in trans to modulate gene expression, epigenetically.

Numerous studies have reported that miRNAs can regulate cancer progression, particularly the processes of growth, invasion, and metastasis \[[@B12-cancers-11-01457]\]. For example, *miR-34a*, which resides on chromosome 1q36.22 and belongs to the *miR-34a* family, has been shown to target the cell cycle regulator, *c-Myc*, in several human cancers \[[@B13-cancers-11-01457],[@B14-cancers-11-01457]\]. In addition, *miR-34a* has also been found to participate in controlling cancer stemness, by targeting CD44 \[[@B15-cancers-11-01457],[@B16-cancers-11-01457],[@B17-cancers-11-01457],[@B18-cancers-11-01457]\].

In this context, *miR-34a* would be considered a tumor suppressor miR in human cancer. Moreover, the promoter region of *miR-34a* contains a CpG island commonly associated with promoter hypermethylation in human cancer \[[@B19-cancers-11-01457]\]. It has also been suggested that *miR-34a* negatively associates with urothelial carcinoma (UC); however, the relationship between the expression of *miR-34a* and its target genes, in UC, has yet to be elucidated. Researchers also have yet to determine the role of epigenetic modification in the expression of *miR-34a*. Consequently, our objective in this study was to determine the role of epigenetic modification in the expression of *miR-34a*, and its target genes, in UC. Unexpectedly, we observed that *miR-34a* is epigenetically controlled by a ceRNA mechanism through the 3′UTR of *c-Myc*, leading to upregulation of *CD44* and cancer progression.

2. Results {#sec2-cancers-11-01457}
==========

2.1. miR-34a Is Epigenetically Silenced in the UMUC3 Cell Line {#sec2dot1-cancers-11-01457}
--------------------------------------------------------------

We first examined expression of the immature miR-34a transcript, pri-*miR-34a*, in a panel of normal bladder urothelial cells (HUCs), and seven human UC cell lines. Surprisingly, compared to primary and immortalized (SV-HUC1) HUC cells, there was a dramatic downregulation of *miR-34a* only in UMUC3 cells, while *miR-34a* expression levels varied in the other cell lines ([Figure 1](#cancers-11-01457-f001){ref-type="fig"}A).

Previous studies have demonstrated that dysregulation of miRNA, through promoter CpG island methylation, is an important mechanism in carcinogenesis \[[@B20-cancers-11-01457]\]. Thus, we sought to identify an epigenetic mechanism downregulating *miR-34a*, in UMUC3 cells. Bisulphite pyrosequencing ([Figure 1](#cancers-11-01457-f001){ref-type="fig"}B), and combined bisulfite restriction analysis (COBRA, [Figure 1](#cancers-11-01457-f001){ref-type="fig"}C) assays were used to determine the methylation status of the CpG island in which *miR-34a* resides. In agreement with the RT-PCR results ([Figure 1](#cancers-11-01457-f001){ref-type="fig"}A), high *miR-34a* methylation levels were observed only in UMUC3 cells. In determining whether DNA methylation was responsible for epigenetic silencing of *miR-34a*, we found that epigenetic treatment with a DNA methyltransferase inhibitor, 5′aza-2′-deoxycytidine (5-AZA), and/or histone deacetylase (HDAC) inhibitor (trichostatin A, TSA), led to robust re-expression of *miR-34a*, in UMUC3 cells only ([Figure 1](#cancers-11-01457-f001){ref-type="fig"}D), due to demethylation of the *miR-34a* promoter region ([Figure 1](#cancers-11-01457-f001){ref-type="fig"}E). These results suggest that *miR-34a* is epigenetically silenced in UMUC3 cells.

Further clinical studies, using 55 UC patient samples, found the *miR-34a* promoter to be devoid of DNA hypermethylation, with only few samples having methylation levels \> 50% ([Figure 1](#cancers-11-01457-f001){ref-type="fig"}F). Interestingly, one group of samples (*n* = 35) had low miR-34a expression, regardless of promoter methylation level ([Figure 1](#cancers-11-01457-f001){ref-type="fig"}F, red dot). After exclusion of those samples, the remaining samples (*n* = 20) showed an inverse correlation between miR-34a expression and promoter methylation ([Figure 1](#cancers-11-01457-f001){ref-type="fig"}G, r = −0.31). Together, these studies of UC cell lines and patient samples showed that even lowly expressing miR-34a samples were devoid of high levels of DNA methylation. Thus, an alternative mechanism may be involved in the suppression of *miR-34a* function in UC.

2.2. c-Myc Acts as a ceRNA of CD44 in Urothelial Carcinoma {#sec2dot2-cancers-11-01457}
----------------------------------------------------------

One recent study revealed that mRNAs compete for binding to a shared set of miRNAs, thereby modulating miRNA-based regulation by acting as competing endogenous RNAs (ceRNAs) \[[@B21-cancers-11-01457]\]. We therefore hypothesized that a ceRNA mechanism may be responsible for regulating *miR-34a* in UC. We then conducted a search of the intersection of three databases (TargetScan, miRanda, and PicTar) to identify any *miR-34a* targets overexpressed in UC. Interestingly, numerous studies have reported that *c-Myc,* a known *miR-34a* target \[[@B22-cancers-11-01457]\], is amplified and upregulated in UC \[[@B23-cancers-11-01457],[@B24-cancers-11-01457]\]. To determine whether *miR-34a* targets the *c-Myc* 3′UTR, in UC, we overexpressed *miR-34a* in UMUC3 cells with low *miR-34a* expression ([Figure 2](#cancers-11-01457-f002){ref-type="fig"}A). As expected, transfection of *miR-34a* reduced mRNA and protein levels of *c-Myc* in UMUC3 cells ([Figure 2](#cancers-11-01457-f002){ref-type="fig"}B). Studies have also shown that the stem cell marker, CD44 is a *miR-34a* target in UC \[[@B17-cancers-11-01457]\]. Indeed, overexpression of *miR-34a* was shown to reduce both mRNA and protein of CD44 in UMUC3 cells ([Figure 2](#cancers-11-01457-f002){ref-type="fig"}C). Taken together, these results suggest that *miR-34a* targets *c-Myc* and CD44 in UC.

The above results indicate that the ectopic expression of *miR-34a* repressed both *c-Myc* and CD44 in UC. Therefore, it was reasonable to assume a significantly positive correlation between *CD44* and *c-Myc* (both targets of *miR-34a* and thus ceRNAs), in UC. To elucidate this ceRNA mechanism, we exogenously overexpressed the *c-Myc* and *CD44* 3′-UTRs, in TCCSUP and TSGH8301 UC cells having high endogenous *miR-34a* expression. Interestingly, overexpression of these 3′-UTRs significantly upregulated the expression of both *CD44* and *c-Myc* mRNA and protein, in TCCSUP ([Figure 3](#cancers-11-01457-f003){ref-type="fig"}A--C) and TSGH8301 ([Figure 3](#cancers-11-01457-f003){ref-type="fig"}D,E) cells. Notably, these events were not due to a decrease, but slight increase, in *miR-34a* expression, both in pre-*miR-34a* and fully mature *miR-34a* ([Figure 4](#cancers-11-01457-f004){ref-type="fig"}A,B). Taken together, these results demonstrate that overexpression of *c-Myc* 3′UTR leads to increased activation of CD44, and vice versa.

2.3. Dicer Knockdown Abolishes ceRNA Effect in UC {#sec2dot3-cancers-11-01457}
-------------------------------------------------

To determine whether *c-Myc* acts as a ceRNA of CD44 through *miR-34a*, we disrupted miRNA biogenesis via knockdown of the double-strand RNA endoribonuclease, *Dicer* \[[@B25-cancers-11-01457]\], in TCCSUP and TSGH8301 cells. RT-PCR confirmed significant suppression of *Dicer* mRNA expression in both cell types transiently infected with anti-*Dicer* shRNAs ([Figure 5](#cancers-11-01457-f005){ref-type="fig"}A,D). Compared to the negative-control (shGFP), overexpression of the *c-Myc* 3′UTR did not increase *CD44* levels in *Dicer*-depleted TCCSUP ([Figure 5](#cancers-11-01457-f005){ref-type="fig"}B) or TSGH8301 ([Figure 5](#cancers-11-01457-f005){ref-type="fig"}E) cells. Reciprocally, overexpression of the *CD44* 3'UTR did not increase *c-Myc* levels in either Dicer-knocked down cell line ([Figure 5](#cancers-11-01457-f005){ref-type="fig"}C,F). It is also noteworthy that TSGH8301 cells (with lower *Dicer* knockdown efficiency), had increased *c-Myc* and *CD44* expression levels, following overexpression of either 3′UTR, in poorly knocked down *Dicer* cells ([Figure 5](#cancers-11-01457-f005){ref-type="fig"}D--F). Taken together, these results confirm that *c-Myc* and *CD44* act as ceRNAs, through *miR-34a*, in UC.

2.4. Expression of c-Myc Correlates with Expression of CD44, in Samples from UC patients and Cell Lines {#sec2dot4-cancers-11-01457}
-------------------------------------------------------------------------------------------------------

We also examined the ceRNA mechanism, in vivo, by assessing the expression of *c-Myc* and *CD44* in samples obtained from 55 UC patients. Consistent with our cell line study, the expression of *c-Myc* in the clinical samples positively correlated with the expression of *CD44* (R^2^ = 0.1015, *p* \< 0.05, [Figure 6](#cancers-11-01457-f006){ref-type="fig"}A). 3D scatter plot analysis of these samples also revealed a positive correlation between the expression of *miR-34a* and the expression of *c-Myc* and *CD44* ([Figure 6](#cancers-11-01457-f006){ref-type="fig"}B), although no correlation between expression of these genes with any of the clinical-pathological parameters was found ([Table 1](#cancers-11-01457-t001){ref-type="table"}). Similar findings were obtained from a gene expression array (GDS1479, [Figure 6](#cancers-11-01457-f006){ref-type="fig"}C) and RNA-Seq dataset (from TCGA, [Figure 6](#cancers-11-01457-f006){ref-type="fig"}D). We also investigated the expression of *c-Myc* and *CD44* in HUC1, normal urothelial cells and various UC cell lines ([Figure 6](#cancers-11-01457-f006){ref-type="fig"}E). Except for the J82 cell line, which has surprisingly low levels of *c-Myc* expression ([Figure 6](#cancers-11-01457-f006){ref-type="fig"}E, green dot), all cells demonstrated a positive correlation between *c-Myc* and *CD44* expression, in UC cells (*r* = 0.672). In light of the strong association between c-Myc and the aggressiveness of cancer and eventual prognosis \[[@B26-cancers-11-01457]\], we also examined the correlation between the expression of *c-Myc* and tumor recurrence in this sample cohort. Kaplan--Meier survival analysis revealed an association between higher *c-Myc* expression levels and poor recurrence-free survival (*p* \< 0.05, [Figure 6](#cancers-11-01457-f006){ref-type="fig"}F).

2.5. Dominant-Negative p53 Mutation Downregulates miR-34a in UC {#sec2dot5-cancers-11-01457}
---------------------------------------------------------------

Our previous experiment, using clinical samples, found a group of UC patient samples with low *miR-34a* expression, but also low *miR-34a* promoter methylation. This occurrence suggested an alternative mechanism(s) of controlling miR-34a expression in UC. In that regard, the *miR-34a* promoter was found to possess a perfect p53-binding site \[[@B27-cancers-11-01457]\] and be directly regulated by the tumor suppressor p53 \[[@B28-cancers-11-01457]\]. To determine whether p53 could regulate *miR-34a* expression, and the subsequent expression of *c-Myc* and *CD44*, we stably transfected *p53* mutants (*p53*R175H and *p53*R273H) into TSGH8301 UC cells, with endogenous wild-type *p53* \[[@B29-cancers-11-01457]\], to create a dominant-negative effect. Compared to the control, overexpression of the *p53* mutant downregulated *miR-34a* expression, while upregulating *CD44* and *c-Myc* ([Figure 7](#cancers-11-01457-f007){ref-type="fig"}). These results confirmed that p53 regulates *miR-34a* expression directly, and subsequently, miR-34a's capability of downregulating *CD44* and *c-Myc* expression, in UC cells.

2.6. miR-34a Suppresses Tumorigenicity and Drug Resistance in UC {#sec2dot6-cancers-11-01457}
----------------------------------------------------------------

*miR-34a* has been reported to be a key regulator of tumor suppression, and its downregulation has been linked to the occurrence and development of several cancers \[[@B30-cancers-11-01457]\]. Here, we sought to elucidate the functional role of *miR-34a*, in UC, by stably overexpressing *miR-34a* in UMUC3 cells. Such overexpression significantly inhibited cell growth ([Figure 8](#cancers-11-01457-f008){ref-type="fig"}A), and anchorage-independent growth ([Figure 8](#cancers-11-01457-f008){ref-type="fig"}B). It also significantly inhibited the invasive ability of UMUC3 cells ([Figure 8](#cancers-11-01457-f008){ref-type="fig"}C) and resensitized them to the effects of cisplatin ([Figure 8](#cancers-11-01457-f008){ref-type="fig"}D). Finally, a nude mouse model demonstrated that *miR-34a* overexpression inhibited the growth of UMUC3 cell xenografts in vivo ([Figure 8](#cancers-11-01457-f008){ref-type="fig"}E). Overall, these findings revealed that *miR-34a* overexpression inhibited both the growth and invasive ability of cancer cells, while also reducing chemoresistance in UC cells.

3. Discussion {#sec3-cancers-11-01457}
=============

*miR-34a* plays an important role in cancer progression and drug resistance. Previous studies have reported *miR-34a* downregulation in many cancer types \[[@B31-cancers-11-01457]\], including urothelial cancer (UC) \[[@B32-cancers-11-01457]\]. Epigenetic silencing of *miR-34a* has also been addressed in several previous studies of human cancer \[[@B19-cancers-11-01457],[@B33-cancers-11-01457],[@B34-cancers-11-01457]\]; however, the mechanism underlying *miR-34a* downregulation, in UC, has yet to be elucidated. In this study, when evaluating *miR-34a* expression in seven UC cell lines, we were surprised to observe epigenetic silencing of *miR-34a*, via promoter hypermethylation, only in UMUC3 UC cells. Clinical analyses also found that most UC patient samples were devoid of promoter *miR-34a* hypermethylation. For UC cells (BFTC905 and J82) and patient samples showing low expression, but also low *miR-34a* promoter methylation, the possibility of other epigenetic mechanisms (e.g., histone modifications), in regulating *miR-34a*, cannot be excluded. Since *miR-34a* is expressed in most UC cell lines and patient samples, alternative mechanisms likely exist for controlling *miR-34a* function in UC.

A new type of miRNA regulation, referred to as a competitive endogenous RNA (ceRNA) mechanism, involves crosstalk between miRNA targets and the regulation of gene expression, through competition in binding to shared miRNAs has recently been described \[[@B35-cancers-11-01457]\]. Several research groups, including ours, have reported this phenomenon in human cancers \[[@B36-cancers-11-01457],[@B37-cancers-11-01457],[@B38-cancers-11-01457],[@B39-cancers-11-01457]\]. In particular, we recently demonstrated that estrogen receptor-driven upregulation of *E2F6* can 'sponge' *miR-193a*, to facilitate *c-Kit* overexpression, in ovarian cancer \[[@B36-cancers-11-01457]\]. In the current study, we demonstrated that overexpression of the *c-Myc* 3′UTR could upregulate *CD44* through *miR-34a*. Importantly, we also observed a positive correlation between the expression of *c-Myc* and *CD44* in samples from UC patients and cell lines. Taken together, our results indicate that *c-Myc* may act as a ceRNA of *CD44*, in UC.

Several *miR-34a* targets have been shown to control the function of *miR-34a*, through ceRNA mechanisms. For example, one oncogenic, long noncoding (lnc)RNA (lncRNA-SNHG7) has been shown to sponge *miR-34a*, upregulating the expression of the oncogene *GALNT7* in colorectal cancer \[[@B40-cancers-11-01457]\]. In another study, lnc015192 was shown to sponge *miR-34a* to upregulate *Adam12* expression in breast cancer \[[@B41-cancers-11-01457]\]. However, the current study was the first to demonstrate that *c-Myc* mRNA can act as a ceRNA, to upregulate *CD44* expression, by targeting *miR-34a*, in UC. Our results indicate that *c-Myc* participates in cancer stemness, not only via protein regulation \[[@B42-cancers-11-01457],[@B43-cancers-11-01457],[@B44-cancers-11-01457]\], but also via mRNA. Note that the genomic amplification of chromosome 8q (where *c-Myc* resides), commonly associated with UC, provides an additional driving force for the overexpression of *CD44* \[[@B23-cancers-11-01457],[@B24-cancers-11-01457]\]. This may also explain the significantly shorter recurrence-free survival of patients presenting high *c-Myc* expression.

As in previous studies, we observed that *miR-34a* overexpression in UC cells inhibited tumor invasion and reduced drug resistance, probably through the inhibition of CD44 \[[@B15-cancers-11-01457],[@B16-cancers-11-01457],[@B17-cancers-11-01457]\]. In the future, it may be possible to implement epigenetic interventions to restore *miR-34a* expression, and inhibit cancer stemness, in a subset of UC patients with epigenetic silencing of this micro-RNA \[[@B16-cancers-11-01457]\].

On the other hand, the tumor suppressor gene *p53*, the most frequently mutated tumor suppressor in human cancer, including urothelial carcinoma \[[@B45-cancers-11-01457],[@B46-cancers-11-01457]\], also directly upregulates *miR-34a* \[[@B47-cancers-11-01457],[@B48-cancers-11-01457],[@B49-cancers-11-01457]\], thereby explaining the fact that p53 signaling can control *miR-34a* expression, in UC samples, without *miR-34a* promoter methylation. In this regard, overexpression of a dominant-negative *p53* mutant resulted in *miR-34a* downregulation, and the subsequent upregulation of *CD44* and *c-Myc*, in UC cells with wild-type p53.

It is also noteworthy to point out that the ceRNA effect of *c-Myc* and *CD44* overexpression, by the *c-Myc* 3′UTR, in UC cell lines ([Figure 4](#cancers-11-01457-f004){ref-type="fig"}A,B), was not due to a decrease---but surprisingly, a slight increase---of *mR-34a* expression in those cells. This phenomenon may be due to the presence of a feedback loop that increases miR-34a expression upon the increase of *c-Myc*/*CD44* \[[@B50-cancers-11-01457]\]. However, further experiments need to be performed to validate such feedback loop.

4. Materials and Methods {#sec4-cancers-11-01457}
========================

4.1. Cell Cultures and Patient Samples {#sec4dot1-cancers-11-01457}
--------------------------------------

Human UC cell lines (SV-HUC, BFTC905, HT1376, TSGH8301, TCCSUP, J82, and UMUC3) were used in this study. SVHUC, BFTC905, HT1376, and TSGH8301 cell lines were maintained in RPMI 1640 medium (Gibco, Grand Island, NY), TCCSUP was maintained in DMEM medium, and J82 and UMUC3 were maintained in MEM medium (Gibco). Cultured cells were supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin-streptomycin, in a humidified atmosphere of 5% CO~2~, at 37 ℃. Fifty-five urothelial cancer samples from bladders or upper urinary tracts (ureter or renal pelvis) were procured from Chia-Yi Christian Hospital, Chia Yi, Taiwan. The clinical-pathological data of all samples is summarized in [Table 2](#cancers-11-01457-t002){ref-type="table"}. All tissue samples were acquired from either transurethral resection (TURBT) or radical surgery. Patients were then followed up by either cystoscopy or radiographic detection (CT or MRI) for recurrence. All patients provided informed consent. This human sample study was approved by the Institutional Review Board of Chia-Yi Christian hospital, Taiwan.

4.2. Plasmid Constructs and shRNA Knockdown {#sec4dot2-cancers-11-01457}
-------------------------------------------

The *miR-34a* full-length DNA sequence was amplified via PCR with specific primers ([Table 3](#cancers-11-01457-t003){ref-type="table"}) inserted into pSilencer4.1 as miRNA expression vectors. The *CD44* 3′UTR and *c-Myc* 3′UTR regions (each of which contains two *miR-34a* binding sites) were ligated into EGFP-C1. All shRNA plasmids in the pLKO.1 plasmid were purchased from the National RNAi Core Facility at Academia Sinica, Taiwan (rnai.genmed.sinica.edu.tw) and the clone IDs were *Dicer*-1 TRCN0000290426 and *Dicer*-2 TRCN0000290486).

4.3. RNA Expression {#sec4dot3-cancers-11-01457}
-------------------

All RNA samples were extracted with TRIzol Reagent (Invitrogen, Carlsbad, CA), according to the manufacturer's instructions. The expression of *CD44* and *c-Myc,* in UC cell lines, was analyzed by RT-PCR, using the StepOne Real-Time PCR System (Applied Biosystems, Waltham, MA, USA) with specific primers ([Table 3](#cancers-11-01457-t003){ref-type="table"}). Relative gene expression levels were determined by comparing the threshold cycle (i.e., Ct value) of the test gene, normalized to the Ct of GAPDH, in each sample.

4.4. DNA Methylation Analysis {#sec4dot4-cancers-11-01457}
-----------------------------

All DNA was extracted using Genomic DNA Mini Kits (Geneaid, Taipei, Taiwan) according to the manufacturer's instructions, and underwent bisulfite modification, using EZ DNA Methylation-Gold™ kits (Zymo Research, Orange, CA, USA), according to the manufacturer's protocol. Combined Bisulfite Restriction Analysis (COBRA) was used to determine *miR-34a* promoter methylation status, through digestion using *Bst*UI (New England BioLabs, Beverly, MA, USA). Digested products were separated on 1.5% agarose gels for visualization. Pyrosequencing was performed using the PyroMark Q24 (Qiagen, GmbH, Hilden, Germany), with Pyro Gold Reagents (Qiagen), according to the manufacturer's instructions. The methylation status of nine CpG sites, proximal to *miR-34a*, was measured. The methylation percentage of each cytosine was determined by the fluorescence intensity of a cytosine, divided by the sum of fluorescence intensity of cytosines and thymines, at each CpG site (multiplied by 100%). Primers for methylation analysis are shown in [Table 3](#cancers-11-01457-t003){ref-type="table"}.

4.5. Cell Invasion Assay {#sec4dot5-cancers-11-01457}
------------------------

2 × 10^4^ cells were seeded in 1% FBS medium in the upper chamber on 2 Millicell™ matrigel-coated (BD Bioscience, NJ, USA) cell culture inserts (Millipore, Billerica, MA). After 48 h, the cells were fixed using methanol and stained using Giemsa reagent (Sigma, St. Louis, MO, USA).

4.6. Cell Viability Assay {#sec4dot6-cancers-11-01457}
-------------------------

Cells were seeded in 96-well plates for 4 d without or with cisplatin in various concentrations. Cell growth was determined using a cell counting kit (CCK-8, Sigma), according to the manufacturer's instructions. Cell absorbances were then determined at 450 nm, using a microplate reader.

4.7. Soft Agar Assay {#sec4dot7-cancers-11-01457}
--------------------

For soft agar assays, a 3-mL base layer of agar (0.5% agar in culture medium) was allowed to solidify in a six-well flat-bottomed plate, before the addition of 2.0-mL cell suspensions (10,000 cells) in 0.3% agar in culture medium. The cell-containing layer was then solidified at room temperature for 20 min. Colonies were allowed to grow for 14--21 days at 37 °C with 5% CO~2~ before imaging. Plates were then stained with 1 mg/mL iodonitrotetrazolium chloride (Sigma) overnight at 37 °C.

4.8. Western Blotting {#sec4dot8-cancers-11-01457}
---------------------

All samples were lysed using PRO-PREP Protein Extraction Solution (iNtRON Biotechnology, Korea), and then immunoblotted, using monoclonal primary antibodies (CD44, GAPDH, and Dicer), purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA), and Myc (Abcam, Cambridge, UK). Horseradish peroxidase-conjugated secondary antibodies, including mouse IgG and rabbit IgG antibodies (Abcam), were also used. Specific signals were visualized using a chemiluminescence (ECL) detection kit (Millipore) and the BioSpectrum^®^ 2D Imaging System (BioSpectrum 800, UVP, Upland, CA, USA).

4.9. Bioinformatics Analysis {#sec4dot9-cancers-11-01457}
----------------------------

The output results of multiple prediction programs were integrated using TargetScan (<http://www.targetscan.org/>), PicTar (<http://pictar.org/>), and miRanda (<http://www.microrna.org/microrna/>), to precisely identify miRNAs targeting *c-Myc* and *CD44*. Moreover, results of other microRNAs found in these three databases were retrieved and compared.

4.10. In Vivo Tumorigenicity Assay {#sec4dot10-cancers-11-01457}
----------------------------------

Eight-week-old, athymic nude mice (BALB/cByJNarl) were obtained from the Taiwan National Laboratory Animal Center or BioLASCO Taiwan Co., Ltd., Taipei, Taiwan. All mice were kept under specific pathogen-free conditions, using a laminar airflow rack, with free access to sterilized food and autoclaved water. All animal experiments were approved by the Animal Experimentation Ethics Committee of National Chung Cheng University (Taiwan). 1 × 10^6^ cells, in a 1:1 mixture of 0.1 mL medium and Matrigel (BD Biosciences), were injected subcutaneously into each flank of each mouse (day 0). Tumor size was measured daily, using calipers, in length (L) and width (W). Tumor volumes were calculated using the formula (L × W2/2). At the end of the experiments, all mice were sacrificed by cervical dislocation, as previously approved.

4.11. Statistical Calculation {#sec4dot11-cancers-11-01457}
-----------------------------

All statistical analysis was performed using GraphPad (San Diego, CA, USA) Prism 5 software (version 5.01). Non-parametric variables were assessed using the Mann--Whitney test, when appropriate. Recurrence-free survival was assessed using Kaplan-Meier analysis with log-rank test. A *p* value of less than 0.05 was considered significant.

5. Conclusions {#sec5-cancers-11-01457}
==============

In conclusion, *miR-34a* was epigenetically silenced only in a subset of UC cell lines and patient samples. Moreover, overexpression of *c-Myc* was shown to upregulate *CD44*, via a *miR-34a*-mediated ceRNA mechanism, in UC cell lines and clinical samples. The overexpression of *miR-34a* was also shown to suppress tumor growth and invasive capability, while reducing drug resistance. Thus, amplification of *c-Myc* is an important mechanism in controlling cancer stemness, through ceRNA mechanisms, in UC. These novel modes of endogenous competition could explain the regulation of any number of genes, both in healthy and diseased tissues.
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![miR-34a is epigenetically silenced by promoter DNA methylation in UMUC3 cell lines, and a subset of urothelial carcinoma (UC) patient samples. (**A**) Expression of pri-*miR-34a* in normal HUC1 bladder cells and various UC cell lines, relative to GAPDH, as an internal control. Methylation analysis of the *miR-34a* promoter in various UC cell lines, using (**B**) bisulphite pyrosequencing and (**C**) COBRA assay. The upper panel in (**B**) presents the genomic structure of the *miR-34a* promoter, with the corresponding locations of all CpG sites from −200 to +400. The lower panel in (**B**) illustrates DNA methylation at each CpG site (circle) of various cells, where the intensity of the blue color indicates the degree of methylation. The CpG sites interrogated by bisulphite prosequencing are also indicated. In the COBRA assays in (**C**), bisulphite-modified DNA was amplified via PCR and digested using *Bst*UI. U, undigested control; C, digested using *Bst*UI; M, DNA ladder marker; *IVD*, in vitro methylated DNA. (**D**) Expression of pri*-miR-34a* in UC cell lines, following epigenetic treatment. UC cell lines treated with 5-aza-2'-deoxycytidine (5aza) and/or trichostatin A (TSA) were examined for pri*-miR-34a* expression, using qRT-PCR. Error bars represent standard deviations calculated from duplicates. (**E**) Bisulphite pyrosequencing analysis of the *miR-34a* promoter in UMUC3 cells treated with various epigenetic drugs, as in (**D**). (**F**) Scatter plot showing expression and promoter methylation of *miR-34a* in 55 urothelial carcinoma patient samples, showing a distinct group of patient samples (red dots) with both low expression and low promoter methylation of *miR-34a*. Analysis of the other patient samples (methylated) showed an inverse correlation (r = −0.31) between expression and methylation of *miR-34a*, as shown in (**G**).](cancers-11-01457-g001){#cancers-11-01457-f001}

![miR-34a targets both *c-Myc* and *CD44*, in UMUC3 urothelial cancer cells. (**A**) Expression of mature miR-34a in UMUC3 cells overexpressing pri-*miR-34a* or an empty vector (NC). Overexpression of miR-34a led to the downregulation of (**B**) c-Myc and (**C**) CD44. Upper panel, RT-PCR; lower panel, western blot analysis. GAPDH was used as a loading control for western blot analysis. (\*\*\* *p* \< 0.001).](cancers-11-01457-g002){#cancers-11-01457-f002}

![*c-Myc* acts as a ceRNA of *CD44* in urothelial carcinoma cells. TCCSUP (**A**--**C**) or TSGH8301 (**D**--**F**) UC cells overexpressing the *c-Myc* 3′UTR or *CD44* 3′UTR. Expression of CD44 and c-Myc, as evaluated using RT-PCR (mRNA, **A**,**B**,**D**,**E**), and eestern blot analysis (protein, **C**,**F**). GAPDH was used as loading control for western blot analysis. (\*\* *p* \< 0.01, \*\*\* *p* \< 0.001).](cancers-11-01457-g003){#cancers-11-01457-f003}

![Overexpression of *c-Myc* or *CD44* 3′-UTRs do not suppress *miR-34a* expression in urothelial carcinoma cells. Pri-*miR-34a* and mature *miR-34a* were both detected in (**A**) TCCSUP and (**B**) TSGH8301 urothelial carcinoma cells overexpressing *c-Myc* or *CD44* 3′-UTRs. (\* *p* \< 0.05; \*\* *p* \< 0.01; \*\*\* *p* \< 0.001).](cancers-11-01457-g004){#cancers-11-01457-f004}

###### 

Dicer knockdown diminishes the ceRNA effects of *c-Myc* and *CD44* in urothelial carcinoma cells. Dicer was depleted by shRNA in TCCSUP and TSGH8301 urothelial carcinoma cells. Relative expression of Dicer was assessed in (**A**) TCCSUP and (**D**) TSGH8301 cells using RT-PCR. Expression of *CD44* (**B**,**E**) and *c-Myc* (**C**,**F**) in the control and Dicer-depleted cells was also assessed using RT-PCR. (\* *p* \< 0.05; \*\* *p* \< 0.01, \*\*\* *p* \< 0.001).
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###### 

Positive correlation between c-Myc and CD44 expression in samples from urothelial carcinoma patients. (**A**) Scatter plot analysis revealed a positive association between the expression of *c-Myc* and *CD44* (*r* = 0.318, *p* \< 0.05) in samples obtained from 55 UC cancer patients at Chia-Yi Christian Hospital (CYCH), Taiwan. (**B**) 3D scatter plot showing positive correlations between *c-Myc*, *CD44*, and *miR-34a* in this cohort of UC patient samples. A positive correlation between the expression of *c-Myc* and *CD44* was also observed in samples obtained from two publicly available databases (**C**) GEO GDS1479 (60 samples, expression microarray, *r* = 0.578, *p* \< 0.05) and (**D**) TCGA (411 samples, RNA-Seq, *r* = 0.5039, *p* \< 0.001). (**E**) Scatter plot showing the expression *CD44* in UC cell lines. Except for J82 cells (green dot), which showed an exceptionally low expression of *c-Myc*, all other cells showed a positive correlation between expression of these genes (*r* = 0.672). (**F**) Kaplan--Meier survival analysis indicating that higher *c-Myc* expression associates with poor recurrence-free survival (*p* \< 0.05).
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![p53 controls *miR-34a* expression in TSGH8301 urothelial carcinoma cells. Co-expression of p53 mutants p53R175H or p53R273H, with wild-type p53, in TSGH8301 cells, downregulated *miR-34a* and upregulated *CD44* and *c-Myc*, as determined by RT-PCR. \* *p* \< 0.05; \*\* *p* \< 0.01.](cancers-11-01457-g007){#cancers-11-01457-f007}

###### 

Overexpression of miR-34a suppresses tumorigenicity and drug resistance in UMUC3 UC cells. (**A**) Cell proliferation of UMUC3 cells stably expressing *miR-34a* or an empty vector was measured using cell counting kits (CCKs), on the designated days. Anchorage-independent growth in UMUC3 cells overexpressing *miR-34a* was determined using soft-agar (**B**) and cell invasion (magnification 100×) (**C**) assays. Quantitative analysis of the number of colonies in the soft agar and invasion assays indicated below. (**D**) Chemosensitivity to cisplatin in UMUC3 cells overexpressing miR-34a, as determined using a CCK. (**E**) Nude mouse xenograft model showing tumor sizes of UMUC3 cells overexpressing *miR-34a* (red line) or a control plasmid (blue line). Representative examples of nude mice bearing tumors are also presented (left: miR-34a, red arrow head; right: control, blue arrow head). \* *p* \< 0.05; \*\* *p* \< 0.01, \*\*\* *p* \< 0.001.
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###### 

Correlation between the expression of *miR-34a*, *c-Myc*, *CD44*, and clinical-pathological data in 55 UC samples.

                           miR-34a             c-Myc       CD44
  ------------------------ ------------------- ----------- ---------------
  **Gender**                                               
  Male                     130.2 ± 173.6 ^1^   8.4 ± 4.1   457.3 ± 1.6
  Female                   31.1 ± 67.5         6.1 ± 1.8   23.8 ± 42.6
  **Location**                                             
  Bladder                  106.9 ± 157.8       1.7 ± 5.5   512.5 ± 1.7
  Upper Tract              105.1 ± 169.1       1.6 ± 6.2   33.8 ± 44.2
  **Histological Grade**                                   
  Low Grade                143.7 ± 198.1       2.3 ± 7.6   108.1 ± 270.1
  High Grade               100.2 ± 149.8       1.7 ± 5.5   413.5 ± 1.6
  **Pathological Stage**                                   
  Stage T1                 90.9 ± 149.2        1.7 ± 5.9   68.9 ± 179.1
  ≥Stage T2                132.2 ± 173.5       1.2 ± 5.3   680.5 ± 2.1
  **Relapse**                                              
  Yes                      108.6 ± 153.1       1.4 ± 3.4   566.1 ± 1.8
  No                       102.7 ± 174.4       1.5 ± 5.8   17.9 ± 22.9

^1^ Relative expression value, Mean ± SD.
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###### 

Summary of clinical-pathological data of urothelial carcinoma samples.

  Clinical Parameter           Patient Samples (*n* = 55)
  ---------------------------- ----------------------------
  **Age \***                   70.94 ± 11.8 ^4^
  Median                       74
  Range                        40--90
  **Gender \***                
  Male                         41
  Female                       13
  **Location ^1,^\***          
  Bladder                      36
  Upper Tract                  18
  **Histological Grade ^2^**   
  Low Grade                    12
  High Grade                   43
  **Pathological Stage**       
  Stage T1                     30
  ≥ Stage T2                   25
  **Relapse \***               
  Yes                          33
  No                           21
  **Treatment**                
  TURBT                        34
  Non-TURBT ^3^                21

^1^ Upper urinary tract UC from ureter or renal pelvis; ^2^ Grading, low grade: G1, high grade: ≥G2; ^3^ Radial cystectomy (*n* = 2) or nephroureterectomy with bladder cuff excision (*n* = 19); ^4^ Mean ± SD. \* 1 case was missing a value.
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###### 

Primers used in this study

  Primer Name                      Primer Sequence (5′ to 3′)                   Annealing TEMP (°C)   Product Size (bp)
  -------------------------------- -------------------------------------------- --------------------- -------------------
  **COBRA**                                                                                           
  miR-34a-BS-F                     TTTTTTTTTTTAGGTGGAGGAG                       60                    270
  miR-34a-BS-R                     ATACAAACTTCCAAACCTCTCC                                             
  **Bisulphite Pyrosequeincing**                                                                      
  miR-34a-Pyro-F                   TAGGTGGGGGTTAGGTAG                           64                    87
  miR-34a-Pyro-R ^1^               agctggacatcacctcccacaacgCAAACTCCCACCCCTCCC                         
  miR-34a-SEQ                      GGTAGGGAGTATGAAG                                                   
  **RT-PCR**                                                                                          
  pri-miR-34a RT-F                 TGTGATTAACCCCGTCTTGCA                        60                    101
  pri-miR-34a RT-R                 GCAGATTCTTGAGCCAGATTGC                                             
  CD44-RT-F                        TCCCAGTATGACACATATTGC                        60                    129
  CD44-RT-R                        CACCTTCTTCGACTGTTGAC                                               
  c-Myc-RT-F                       CTCGGATTCTCTGCTCTCTCCTCG                     60                    177
  c-Myc-RT-R                       TCTGACCTTTTGCCAGGAGCCT                                             
  Dicer-RT-F                       TTAACCTTTTGGTGTTTGATGAGTGT                   60                    98
  Dicer-RT-R                       GCGAGGACATGATGGACAATT                                              
  GAPDH RT-F                       CCCCTTCATTGACCTCAACTACAT                     60                    135
  GAPDH RT-R                       CGCTCCTGGAAGATGGTGA                                                
  **Plasmid construction**                                                                            
  miR-34a construct                                                                                   
  miR-34a-BamHI F                  CGCGGATCCGTAGAGATGGAGTCTTGCTAGTTGC           64                    514
  miR-34a-HindIII R                CCCAAGCTTTTCTCCCTACGTGCAAACTTCT                                    
  3′UTR construct                                                                                     
  CD44-XhoI F                      CCTCGAGTGATCGTTCCAGTTCCCACTTG                66                    263
  CD44-PstI R                      CCCCTGCAGGGGGGTCTGTTGAAGAT                                         
  c-Myc-XhoI F                     CCTCGAGCTTGAGACTGAAAGATTTAGCCAT              66                    369
  c-Myc-PstI R                     CCCCTGCAGTAAGATTTGGCTCAATGATATATTTG                                

^1^ Primer sequence of the 5′tailed universal primer (UNIVR) is shown as lower case.

[^1]: These authors contributed equally to this work.
